Strategic Biopharma Transactions: Bankruptcy Asset Auctions, GI-Restricted Kinase Mergers, and Oral Immunology Capital

Skye Bioscience and Redx Pharma agreed to a corporate reverse merger supported by a concurrent $125M PIPE financing, giving the combined company the balance sheet to move a late-preclinical to clinical-stage pipeline forward without a near-term dilution event.

The strategic centrepiece is RXC008, a Phase II-ready oral pan-ROCK inhibitor engineered for GI-restricted exposure in fibrostenotic Crohn's disease. GI-restriction is the key value driver: it targets a pathway with strong anti-fibrotic rationale while limiting the systemic cardiovascular liabilities that have historically constrained ROCK inhibition.

PTC Therapeutics acquired ST-920 (isaralgagene civaparvovec), an AAV gene therapy for Fabry disease, through a Section 363 bankruptcy asset auction with a total deal value of $211M.

Section 363 processes continue to be the most efficient route to clinically de-risked assets: buyers acquire clean title free of most legacy liabilities, and pricing is anchored to the auction rather than to the original developer's sunk cost.

In a parallel carve-out from the same estate, Eli Lilly secured the ST-506 prion disease program together with Sangamo's neurotropic capsid and MINT gene-editing platforms for $50M upfront.

The transaction is platform-led rather than asset-led: CNS-crossing capsids and a regulated gene-editing toolkit are enabling technologies that can be applied across Lilly's neuroscience portfolio well beyond the acquired prion program.

Khartis Therapeutics raised a $50M Series B to advance an oral selective IGF-1R inhibitor in Thyroid Eye Disease.

The thesis mirrors a wider immunology trend: displacing infused biologics with orally administered small molecules of comparable target selectivity, trading peak efficacy for convenience, payer economics, and earlier lines of therapy.

Deerfield Management launched Boulevard Bio with $65M in Series A capital behind BLVD101, a BAFF/APRIL bispecific, and BLVD201, a trispecific engager.

Dual B-cell cytokine blockade continues to attract capital as a route to durable, reset-style responses in autoimmune disease, positioned as an alternative to autologous cell therapy logistics.

Zealand Pharma monetized royalty rights to Rusfertide (PTG-300) with Royalty Pharma for $100M upfront.

Synthetic royalty structures remain the preferred non-dilutive financing instrument for commercial-stage biotech, converting a defined future cash flow into immediate capital without equity issuance or restrictive debt covenants.

InduPro closed a $77M Series B to advance IDP-001, a proximity-guided bispecific antibody-drug conjugate.

Proximity-guided targeting is the next iteration of ADC design: dual-antigen engagement narrows the therapeutic payload to tumour tissue and widens the therapeutic index relative to single-antigen conjugates.

Jasper Therapeutics and Kira Pharmaceuticals agreed to a business combination financed by a $132M PIPE.

The combined pipeline pairs briquilimab, a c-Kit monoclonal antibody, with Kira's complement pathway inhibitors, creating a mast-cell and complement-focused immunology platform with a shared clinical development infrastructure.